New Rhode Island Life Sciences Hub Board Recruitment Search Company independantexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from independantexpress.com Daily Mail and Mail on Sunday newspapers.
The government’s policy to fast track “innovative” drugs into the NHS to showcase the UK as a great place for industry has been described as “a pretty spectacular failure,” because of the way a test case using the cholesterol lowering drug inclisiran was received.
The rapid introduction of inclisiran into the UK was part of the government’s drive to help the country regain its “status as a science superpower” after Brexit,1 which would bypass some of the usual routes to getting a drug into clinical practice.
The policy was widely supported across government, including by the Department of Health and Social Care, the Department for International Trade, NHS England, the Department of Business, Energy and Industrial Strategy, the Department of Science, Innovation and Technology, and the Office for Life Sciences.
Emails from 2021 obtained through freedom of information requests show that the health minister James Bethell had a meeting with Novartis where using “the UK�
Professor Atholl Johnston, President of the Clinical & Contract Research Association (CCRA), said in response to the announcement of this initiative, made by the Office of Life Sciences. “The CCRA greatly welcomes the review, announced last week, into commercial clinical trials in the UK. The review will be led by .